Discovery of Lanraplenib (GS-9876): A Once-Daily Spleen Tyrosine Kinase Inhibitor for Autoimmune Diseases

被引：31

作者：

Blomgren, Peter ^{[1
]}

Chandrasekhar, Jayaraman ^{[1
]}

Di Paolo, Julie A. ^{[2
]}

Fung, Wanchi ^{[2
]}

Geng, Guoju ^{[2
]}

Ip, Carmen ^{[2
]}

Jones, Randall ^{[1
]}

Kropf, Jeffrey E. ^{[1
]}

Lansdon, Eric B. ^{[2
]}

Lee, Seung ^{[1
]}

Lo, Jennifer R. ^{[1
]}

Mitchell, Scott A. ^{[1
]}

Murray, Bernard ^{[2
]}

Pohlmeyer, Chris ^{[2
]}

Schmitt, Aaron ^{[1
]}

Suekawa-Pirrone, Kimberly ^{[2
]}

Wise, Sarah ^{[2
]}

Xiong, Jin-Ming ^{[1
,2
]}

Xu, Jianjun ^{[1
,2
]}

Yu, Helen ^{[2
]}

Zhao, Zhongdong ^{[1
,2
]}

Currie, Kevin S. ^{[1
]}

机构：

[1] Gilead Sci, Seattle, WA 98102 USA

[2] Gilead Sci, Foster City, CA 94404 USA

来源：

ACS MEDICINAL CHEMISTRY LETTERS | 2020年 / 11卷 / 04期

关键词：

SYK; kinase inhibitor; solubility; lupus; SYK; ENTOSPLETINIB; GS-9973; POTENT;

D O I：

10.1021/acsmedchemlett.9b00621

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Spleen tyrosine kinase (SYK) is a critical regulator of signaling in a variety of immune cell types such as B-cells, monocytes, and macrophages. Accordingly, there have been numerous efforts to identify compounds that selectively inhibit SYK as a means to treat autoimmune and inflammatory diseases. We previously disclosed GS-9973 (entospletinib) as a selective SYK inhibitor that is under clinical evaluation in hematological malignancies. However, a BID dosing regimen and drug interaction with proton pump inhibitors (PPI) prevented development of entospletinib in inflammatory diseases. Herein, we report the discovery of a second-generation SYK inhibitor, GS-9876 (lanraplenib), which has human pharmacokinetic properties suitable for once-daily administration and is devoid of any interactions with PPI. Lanraplenib is currently under clinical evaluation in multiple autoimmune indications.

引用

页码：506 / 513

页数：8

共 30 条

[1] Update on Lupus Nephritis
Almaani, Salem
Meara, Alexa
Rovin, Brad H.
[J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2017, 12 (05): : 825 - 835
[2] Formulation of solid dosage forms to overcome gastric pH interaction of the factor Xa inhibitor, BMS-561389
Badawy, SIF
Gray, DB
Zhao, F
Sun, DX
Schuster, AE
Hussain, MA
[J]. PHARMACEUTICAL RESEARCH, 2006, 23 (05) : 989 - 996
[3] R406, an orally available spleen tyrosine kinase inhibitor blocks Fc receptor signaling and reduces immune complex-mediated inflammation
Braselmann, Sylvia
Taylor, Vanessa
Zhao, Haoran
Wang, Su
Sylvain, Catherine
Baluom, Muhammad
Qu, Kunbin
Herlaar, Ellen
Lau, Angela
Young, Chi
Wong, Brian R.
Lovell, Scott
Sun, Thomas
Park, Gary
Argade, Ankush
Jurcevic, Stipo
Pine, Polly
Singh, Rajinder
Grossbard, Elliott B.
Payan, Donald G.
Masuda, Esteban S.
[J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 319 (03) : 998 - 1008
[4] PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers
Coffey, Greg
Rani, Aradhana
Betz, Andreas
Pak, Yvonne
Haberstock-Debic, Helena
Pandey, Anjali
Hollenbach, Stanley
Gretler, Daniel D.
Mant, Tim
Jurcevic, Stipo
Sinha, Uma
[J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (02) : 194 - 210
[5] A new look at Syk in αβ and γδ T cell development using chimeric mice with a low competitive hematopoietic environment
Colucci, F
Guy-Grand, D
Wilson, A
Turner, M
Schweighoffer, E
Tybulewicz, VLJ
Di Santo, JP
[J]. JOURNAL OF IMMUNOLOGY, 2000, 164 (10) : 5140 - 5145
[6] Discovery of GS-9973, a Selective and Orally Efficacious Inhibitor of Spleen Tyrosine Kinase
Currie, Kevin S.
Kropf, Jeffrey E.
Lee, Tony
Blomgren, Peter
Xu, Jianjun
Zhao, Zhongdong
Gallion, Steve
Whitney, J. Andrew
Maclin, Deborah
Lansdon, Eric B.
Maciejewski, Patricia
Rossi, Ann Marie
Rong, Hong
Macaluso, Jennifer
Barbosa, James
Di Paolo, Julie A.
Mitchell, Scott A.
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (09) : 3856 - 3873
[7] Discovery and SAR of novel [1,6]naphthyridines as potent inhibitors of Spleen Tyrosine Kinase (SYK)
Cywin, CL
Zhao, BP
McNeil, DW
Hrapchak, M
Prokopowicz, AS
Goldberg, DR
Morwick, TM
Gao, A
Jakes, S
Kashem, M
Magolda, RL
Soll, RM
Player, MR
Bobko, MA
Rinker, J
DesJarlais, RL
Winters, MP
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (08) : 1415 - 1418
[8] Lowering Lipophilicity by Adding Carbon: One-Carbon Bridges of Morpholines and Piperazines
Degorce, Sebastien L.
Bodnarchuk, Michael S.
Cumming, Iain A.
Scott, James S.
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (19) : 8934 - 8943
[9] Suppression of Skin and Kidney Disease by Inhibition of Spleen Tyrosine Kinase in Lupus-Prone Mice
Deng, Guo-Min
Liu, Lena
Bahjat, Frances Rena
Pine, Polly R.
Tsokos, George C.
[J]. ARTHRITIS AND RHEUMATISM, 2010, 62 (07): : 2086 - 2092
[10] DIPAOLO J, 2017, ARTHRITIS RHEUMA S10, V69

← 1 2 3 →